China Life has returned for a $142m series D-plus round for cancer treatment developer Biocytogen, having already co-led its $77m series D round 13 months ago.

Biocytogen, the China-based developer of an antibody drug discovery platform, has closed a RMB970m ($142m) series D-plus round featuring China Life Investment, a vehicle for insurance provider China Life, DealStreetAsia reported today.

The round was led by CMB International, a subsidiary of financial services firm China Merchants Bank, and included the state-owned SDIC Venture Capital, 3E Bioventures Capital, Cowin Capital and Baifu Capital filled out the round.

Founded in 2009, Biocytogen is working on cancer treatments and provides preclinical antibody…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
Email LinkedIn